NASDAQ:CDXS - Codexis Stock Price, Forecast & News

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 1.9% and is now trading at $10.31. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Codexis.

Codexis is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by $0.06. The biotechnology company had revenue of $18.65 million for the quarter, compared to analyst estimates of $21.05 million. Codexis had a negative return on equity of 13.34% and a negative net margin of 17.43%. View Codexis' earnings history.

Codexis issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $78-82 million, compared to the consensus revenue estimate of $82.51 million.

2 equities research analysts have issued twelve-month price targets for Codexis' shares. Their forecasts range from $22.50 to $22.50. On average, they anticipate Codexis' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price. View analysts' price targets for Codexis.

Headlines about CDXS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Codexis earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCodexis.

Codexis saw a increase in short interest in March. As of March 13th, there was short interest totaling 5,621,600 shares, an increase of 5.5% from the February 27th total of 5,330,000 shares. Based on an average daily volume of 453,100 shares, the days-to-cover ratio is currently 12.4 days. Currently, 10.2% of the shares of the stock are sold short. View Codexis' Current Options Chain.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), Antares Pharma (ATRS), Gilead Sciences (GILD), NVIDIA (NVDA) and Catalyst Pharmaceuticals (CPRX).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.47%), William Blair Investment Management LLC (2.96%), Janus Henderson Group PLC (2.57%), Nikko Asset Management Americas Inc. (2.35%), Sumitomo Mitsui Trust Holdings Inc. (2.35%) and FMR LLC (2.33%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prescott Group Capital Management L.L.C., FMR LLC, Oak Ridge Investments LLC, Stifel Financial Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., and Bank of America Corp DE. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, James Lalonde, and Thomas R Baruch. View insider buying and selling activity for Codexis.

CDXS stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Aviva PLC, Essex Investment Management Co. LLC, Goldman Sachs Group Inc., Barclays PLC, and Marshall Wace LLP. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang. View insider buying and selling activity for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $10.31.

Codexis has a market capitalization of $607.26 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe. View additional information about Codexis.

The official website for Codexis is http://www.codexis.com/.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]